Evidence map›Paper›PMID 18535250›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2008

Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.

Markus Diefenbacher, Sylwia Sekula, Christine Heilbock, Jana V Maier, Margarethe Litfin, Hans van Dam, Marc Castellazzi, Peter Herrlich, Olivier Kassel

Abstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57Frontiers in cell and developmental biology · 2021
    Article
  4. Article
  5. Article
  6. Review
  7. Understanding how long-acting βBritish journal of pharmacology · 2016
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Negative regulation by nuclear receptors: a plethora of mechanisms.Trends in endocrinology and metabolism: TEM · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Markus DiefenbacherInstitut für Toxikologie und Genetik, Forschungszentrum Karlsruhe, Hermann-von-Helmholtz Platz 1, D- 76344 Eggenstein-Leopoldshafen, Germany.
Sylwia Sekula
Christine Heilbock
Jana V Maier
Margarethe Litfin
Hans van Dam
Marc Castellazzi
Peter Herrlich
Olivier Kassel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term activator protein (AP)-1 describes homodimeric and heterodimeric transcription factors composed of members of the Jun, Fos, and cAMP response element-binding protein (CREB)/activating transcription factor (ATF) families of proteins. Distinct AP-1 dimers, for instance the prototypical c-Jun:c-Fos and c-Jun:ATF2 dimers, are differentially regulated by signaling pathways and bind related yet distinct response elements in the regulatory regions of AP-1 target genes. Little is known about the dimer-specific regulation of AP-1 activity at the promoter of its target genes. We have previously shown that nTrip6, the nuclear isoform of the LIM domain protein Trip6, acts as an AP-1 coactivator. Moreover, nTrip6 is an essential component of glucocorticoid receptor (GR)-mediated trans-repression of AP-1, in that it mediates the tethering of GR to the promoter-bound AP-1. We have now discovered a striking specificity of nTrip6 actions determined by the binding preference of its LIM domains. We show that nTrip6 interacts only with Fos family members. Consequently, nTrip6 is a selective coactivator for AP-1 dimers containing Fos. nTrip6 also assembles activated GR to c-Jun:c-Fos-driven promoters. Neither nTrip6 nor GR are recruited to a promoter occupied by c-Jun:ATF2. Thus, only Fos-containing dimers are trans-repressed by GR. Thus, the dimer composition of AP-1 determines the mechanism of both the positive and negative regulation of AP-1 transcriptional activity. Interestingly, on a second level of action, GR represses the increase in transcriptional activity of c-Jun:ATF2 induced by c-Jun N-terminal kinase (JNK)-dependent phosphorylation. This repression depends on GR-mediated induction of MAPK phosphatase 1 (MKP-1) expression, which results in c-Jun N-terminal kinase inactivation.

Indexed as

Activating Transcription Factor 2Adaptor Proteins, Signal TransducingAnimalsATPases Associated with Diverse Cellular ActivitiesCell LineDimerizationDual Specificity Phosphatase 1Enzyme ActivationEnzyme InductionHumansJNK Mitogen-Activated Protein KinasesLIM Domain ProteinsMicePromoter Regions, GeneticProteasome Endopeptidase ComplexProtein BindingActivating Transcription Factor 2Adaptor Proteins, Signal TransducingATPases Associated with Diverse Cellular ActivitiesDual Specificity Phosphatase 1Dusp1 protein, mouseJNK Mitogen-Activated Protein KinasesLIM Domain ProteinsProteasome Endopeptidase ComplexProto-Oncogene Proteins c-fosProto-Oncogene Proteins c-junPSMC5 protein, humanReceptors, GlucocorticoidRepressor ProteinsTranscription Factor AP-1Transcription Factors

Identifiers

PMID18535250
PMCPMC2505324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.